This work presents SeizFt—a novel seizure detection framework that utilizes machine learning to automatically detect seizures using wearable SensorDot EEG data. Inspired by interpretable sleep staging, our novel approach employs a unique combination of data augmentation, meaningful feature extraction, and an ensemble of decision trees to improve resilience to variations in EEG and to increase the capacity to generalize to unseen data. Fourier Transform (FT) Surrogates were utilized to increase sample size and improve the class balance between labeled non-seizure and seizure epochs. To enhance model stability and accuracy, SeizFt utilizes an ensemble of decision trees through the CatBoost classifier to classify each second of EEG recording as seizure or non-seizure. The SeizIt1 dataset was used for training, and the SeizIt2 dataset for validation and testing. Model performance for seizure detection was evaluated using two primary metrics: sensitivity using the any-overlap method (OVLP) and False Alarm (FA) rate using epoch-based scoring (EPOCH). Notably, SeizFt placed first among an array of state-of-the-art seizure detection algorithms as part of the Seizure Detection Grand Challenge at the 2023 International Conference on Acoustics, Speech, and Signal Processing (ICASSP). SeizFt outperformed state-of-the-art black-box models in accurate seizure detection and minimized false alarms, obtaining a total score of 40.15, combining OVLP and EPOCH across two tasks and representing an improvement of ~30% from the next best approach. The interpretability of SeizFt is a key advantage, as it fosters trust and accountability among healthcare professionals. The most predictive seizure detection features extracted from SeizFt were: delta wave, interquartile range, standard deviation, total absolute power, theta wave, the ratio of delta to theta, binned entropy, Hjorth complexity, delta + theta, and Higuchi fractal dimension. In conclusion, the successful application of SeizFt to wearable SensorDot data suggests its potential for real-time, continuous monitoring to improve personalized medicine for epilepsy.
Recent advances in deep learning have led to the development of models approaching the human level of accuracy. However, healthcare remains an area lacking in widespread adoption. The safety-critical nature of healthcare results in a natural reticence to put these black-box deep learning models into practice. This paper explores interpretable methods for a clinical decision support system called sleep staging, an essential step in diagnosing sleep disorders. Clinical sleep staging is an arduous process requiring manual annotation for each 30s of sleep using physiological signals such as electroencephalogram (EEG). Recent work has shown that sleep staging using simple models and an exhaustive set of features can perform nearly as well as deep learning approaches but only for some specific datasets. Moreover, the utility of those features from a clinical standpoint is ambiguous. On the other hand, the proposed framework, NormIntSleep demonstrates exceptional performance across different datasets by representing deep learning embeddings using normalized features. NormIntSleep performs 4.5% better than the exhaustive feature-based approach and 1.5% better than other representation learning approaches. An empirical comparison between the utility of the interpretations of these models highlights the improved alignment with clinical expectations when performance is traded-off slightly. NormIntSleep paired with a clinically meaningful set of features can best balance this trade-off by providing reliable, clinically relevant interpretation with robust performance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.